Cochrane · systematic review · CD010525
Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity
Herlihy, DRB, Thomas, M, Tran, QH, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
4
No studies
8
Included studies
NR
No studies 8 · 66.7%Ungraded 0 · 0%Very low 1 · 8.3%Low 3 · 25%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Unfractionated heparin compared to low molecular weight heparin for venous thromboembolism prophylaxis in people undergoing major amputation of the lower extremity
Population: people undergoing major amputation of the lower extremity
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total VTE (fatal and non‐fatal) Unfractionated heparin vs low molecular weight heparin | no estimate extracted | NR | No studies |
DVT (symptomatic, asymptomatic, non‐fatal) (5 to 8 days after surgery) Unfractionated heparin vs low molecular weight heparin | OR 1.23 [0.28, 5.35] | 1 study · 75 participants | Very low Downgraded: risk of bias, imprecision |
PE (symptomatic, asymptomatic, non‐fatal) Unfractionated heparin vs low molecular weight heparin | no estimate extracted | NR | No studies |
All cause mortality Unfractionated heparin vs low molecular weight heparin | no estimate extracted | NR | No studies |
Adverse events Unfractionated heparin vs low molecular weight heparin | no estimate extracted | NR | No studies |
Bleeding (timing not specified) Unfractionated heparin vs low molecular weight heparin | no estimate extracted | NR | No studies |
Heparin compared to placebo for venous thromboembolism prophylaxis in people undergoing major amputation of the lower extremity
Population: people undergoing major amputation of the lower extremity
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total VTE (fatal and non‐fatal) Heparin vs placebo | no estimate extracted | NR | No studies |
DVT (symptomatic, asymptomatic, non‐fatal) Heparin vs placebo | no estimate extracted | NR | No studies |
PE (symptomatic, asymptomatic, non‐fatal) (timing not specified) Heparin vs placebo | OR 0.84 [0.35, 2.01] | 1 study · 134 participants | Low Downgraded: imprecision |
All cause mortality (timing not specified) Heparin vs placebo | no estimate extracted | 1 study · 40 participants | Low Downgraded: risk of bias, imprecision |
Adverse events (timing not specified) Heparin vs placebo | no estimate extracted | NR | No studies |
Bleeding (timing not specified) Heparin vs placebo | no estimate extracted | 1 study · 40 participants | Low Downgraded: risk of bias, imprecision |